Pipeline
Kantify uses its AI foundational model, Sapian™, to discover novel targets and safe drugs.
These drugs are small molecules that are either new entities or existing repurposable molecules.
Target-based drug discovery: Some of our drugs target proteins with a known role in specific indications. In certain cases, these targets were previously undruggable, meaning Sapian™ successfully discovered first-in-class modulators for these targets.
Phenotype-based drug discovery: Some of our programs focus on predicting novel therapeutic targets. In these cases, Sapian™ identifies both novel targets and potent drugs.
Kantify's drugs are either co-owned with partners or fully owned.
We welcome enquiries about our pipeline or about new collaborations. Get in touch via the below contact form.
Target-based drug discovery: Some of our drugs target proteins with a known role in specific indications. In certain cases, these targets were previously undruggable, meaning Sapian™ successfully discovered first-in-class modulators for these targets.
Phenotype-based drug discovery: Some of our programs focus on predicting novel therapeutic targets. In these cases, Sapian™ identifies both novel targets and potent drugs.
Kantify's drugs are either co-owned with partners or fully owned.
We welcome enquiries about our pipeline or about new collaborations. Get in touch via the below contact form.
Program
Indications
Targets
Hits
Stage
Hit Discovery
Lead Optimization
In/Ex Vivo Validation
KAN-ONCO-01
Johns Hopkins University
Oncology
Metastatic Prostate Cancer
Antigen
3 inhibitors
75% hit rate
In Vivo Validation
KAN-ONCO-02
Fully Owned
Oncology
Soft Tissue Sarcoma
Multiple Novel Targets
62.5% target discovery rate
7 modulators
78% hit rate
In Vivo Validation
KAN-ONCO-03
LUMC
Oncology
Pan Cancer
Ubiquitination
First in Class
2 inhibitors
20% hit rate
Lead Optimization
KAN-ONCO-04
CNRS - IGMM & IBMM
Oncology
Pan Cancer
Ubiquitination
Degrader
8 activators / 13 inhibitors / 24 silent binders
18% / 29% / 53% hit rate
Lead Optimization
KAN-ONCO-05
INSERM - Institut Necker
Oncology
Pan Cancer
Kinase
1 activator / 6 inhibitors
5% / 32% hit rate
Lead Optimization
KAN-ONCO-06
Children Hospital Zurich
Oncology
Diffuse Intrinsic Pontine Glioma
Multiple Novel Targets
/
Hit Discovery
KAN-ONCO-07
Fully Owned
Oncology
Pan Cancer
Multiple Novel Targets
/
Hit Discovery
KAN-NEURO-01
CNRS-IPMC
Neurology
ASD
Ubiquitination
First in Class
4 inhibitors
40% hit rate
Lead Optimization
KAN-NEURO-02
INSERM - ITN & IGF
Neuromuscular Disorders
Sodium Channel
First in Class
8 activators / 56 inhibitors
9% / 44% hit rate
In Vivo Validation
KAN-NEURO-03
INSERM - ITN & IGF
Neurology
Orphan Sodium Channel
First in Class
2 inhibitors
12% hit rate
Lead Optimization
KAN-NEURO-04
Istem/CECS
Neuromuscular Disorders
Multiple Novel Targets
35% target discovery rate
/
Hit Discovery
KAN-NEURO-05
University of Antwerp
Fragile-X
Multiple Novel Targets
/
Hit Discovery
KAN-NEURO-06
Horizon Europe Consortium
5 Neuromuscular Disorders
Multiple Novel Targets
/
Hit Discovery
KAN-CARDIO-01
INSERM - ITN & IGF
Cardiology
Calcium Channel
69 inhibitors
96% hit rate
In Vivo Validation
KAN-PLANT-01
IBMCP
Drought Resistance
Drought Stress Protein
First in Class
13 inhibitors
50% hit rate
In Vivo Validation
KAN-PLANT-02
IBMCP
Drought Resistance
Drought Stress Protein
/
Hit Discovery
Hit rate: novel small molecules predicted by Sapian™ vs novel small molecules validated in an in
vitro assay.
Target discovery rate: novel targets predicted by Sapian™ vs novel targets validated in an in vitro assay.
First in class: if the target was previously undrugged.
Target discovery rate: novel targets predicted by Sapian™ vs novel targets validated in an in vitro assay.
First in class: if the target was previously undrugged.